TargetMol

CBL0137 hydrochloride

Product Code:
 
TAR-T4361
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T4361-1mg1mg£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4361-2mg2mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4361-1mL1 mL * 10 mM (in DMSO)£157.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4361-5mg5mg£176.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4361-10mg10mg£253.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4361-25mg25mg£465.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4361-50mg50mg£646.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4361-100mg100mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
CBL0137 activates p53 and inhibits NF-kB (EC50: 0.37/0.47 μM) in the cell-based p53 and NF-kB reporter assays, respectively. It also suppresses histone chaperone FACT.
CAS:
1197397-89-9
Formula:
C21H25ClN2O2
Molecular Weight:
372.89
Pathway:
; NF-κb; Apoptosis
Purity:
0.9935
SMILES:
Cl.CC(C)NCCn1c2ccc(cc2c2cc(ccc12)C(C)=O)C(C)=O
Target:
NF-κB; p53

References

Gasparian AV,etal.Curaxins: anticancer compounds that simultaneously suppress NF-?B and activate p53 by targeting FACT.Sci Transl Med. 2011 Aug 10;3(95):95ra74. Barone TA,etal.Anticancer drug candidate CBL20137, which inhibits histone chaperone FACT, is efficacious in preClinicalal orthotopic models of temozolomide-responsive and -resistant glioblastoma.Neuro Oncol. 2017 Feb 1;19(2):186-196. Burkhart C,etal.Curaxin CBL20137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preClinicalal models of pancreatic cancer.Oncotarget. 2014 Nov 30;5(22):11038-53.